Results 71 to 80 of about 125 (92)

Evaluation of the efficacy of netakimab therapy for psoriasis involving difficult-to-treat sites: A retrospective single-centre study

Meditsinskiy sovet = Medical Council
Introduction. Netakimab is a humanized anti-interleukin-17 monoclonal antibody, approved for the treatment of moderate to severe psoriasis vulgaris. Available data from the literature on the use and efficacy of this drug in the treatment of psoriasis in difficult-to-treat sites are still limited.
O. Yu. Olisova, N. P. Teplyuk, E. V. Grekova, O. S. Yatskova, P. I. Gushcha, I. S. Maximov   +5 more
openaire   +1 more source

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients

Фармация и фармакология (Пятигорск)
The aim of the work was to identify the presence and strength of association between the use of anti-inflammatory genetically engineered biological drugs and the development of secondary bacterial infections in COVID-19 patients.Materials and methods. We
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

Slowing the progression of ankylosing spondylitis during long-term therapy with netakimab: results of the international multicenter randomized double-blind phase III clinical trial BCD-085-5/ASTERA

Современная ревматология
Objective. To evaluate the effect of long-term therapy with netakimab (NTK) on radiographic progression and reduction of inflammatory changes assessed by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS), and to identify ...
V. I. Mazurov, A. M. Lila, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. V. Smirnov, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, R. R. Samigullina, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, V. V. Tyrenko, Yu. N. Lin’kova, A. V. Zinkina-Orikhan, E. A. Fokina, A. V. Eremeeva, P. S. Pukhtinskaia   +31 more
doaj   +1 more source

Comparative assessment of the dynamics of laboratory markers of endothelial dysfunction in patients with psoriasis under the influence of methotrexate and the IL-17A inhibitor netakimab

Russian Journal of Skin and Venereal Diseases
BACKGROUND: Endothelial dysfunction, a key factor in atherosclerotic vascular damage, increases cardiovascular risk in patients with psoriasis. However, studies on clinically measurable indicators of endothelial dysfunction and their changes during systemic therapy in psoriasis are limited and inconsistent.
Olga A. Pritulo, Alexey A. Petrov, Andriy V Petrov, Marwan Y.N. Maraqa   +3 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome

Medical Alphabet
Understanding the pathogenetic relationship between psoriasis and obesity is crucial, as excess weight can reduce the effectiveness of medications, highlighting its clinical significance not only in the context of disease severity but also in relation to therapeutic outcomes, including with the use of genetically engineered biological therapies ...
L. S. Kruglova, A. S. Bridan-Rostovskaya, E. A. Shatokhina   +2 more
exaly   +2 more sources

Experience of the netakimab use in psoriasis and psoriatic arthritis

Klinicheskaya Dermatologiya I Venerologiya, 2021
Khismatullina Z R
exaly   +2 more sources

SAFETY AND EFFICACY OF INTERLEUKIN-17A INHIBITOR (NETAKIMAB) THERAPY FOR MODERATE TO SEVERE PSORIASIS

Bulletin of the Medical Institute of Continuing Education
Purpose. To gain an understanding of the efficacy and safety of Netakimab (interleukin-17A inhibitor) in the treatment of moderate and severe psoriatic skin lesions based on literature review. Materials and methods. Modern Russian and international literature sources on this topic were collected and analysed. Data searches were performed in specialised
A.A. Dzitsoeva, V.T. Bazaev
exaly   +2 more sources

Development of a predictive model for the identification of patients with high risk of psoriatic arthritis and assessment of the efficacy of early treatment with netakimab, IL-17A inhibitor

Klinicheskaya Dermatologiya I Venerologiya
Psoriasis and psoriatic arthritis (PA) are systemic immune-mediated inflammatory diseases, thus PA develops in one third of patients with skin manifestations. Early diagnosis of PA risks is crucial for prevention of disability and quality of life reduction.
Zhukova O V, Potekaev N N, O V Zhukova   +2 more
exaly   +2 more sources

Persistence of skin process remission in patients with moderate and severe psoriasis vulgaris in application of netakimab: a five-year observational study results

Klinicheskaya Dermatologiya I Venerologiya
Effective therapy with netakimab in patients with moderate and severe psoriasis vulgaris ensures a stable clinical remission of the skin process and prevents the development of psoriatic arthritis. Objective. To analyze the data on the use of netakimab from 2020 to 2024 in achieving and maintaining persistent remission of the skin process in patients ...
S.A. Khardikova, V.G. Martynova, V.S. Dmitruk, K.A. Skrylova, A.A. Protasevich, V.I. Shirshkova   +5 more
exaly   +2 more sources

Case report: successful treatment of pustular plantar psoriasis with an interleukin-17A inhibitor, netakimab

Pharmateca, 2023
E V Svechnikova Svechnikova
exaly   +2 more sources